Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deep Shah

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1Deep Shah, Debra Wyatt, Andrew T Baker, et al.
The Indian Journal of Medical Research|March 6, 2020
Informed consent in psychiatry outpatientsSmita N Deshpande, Nagendra Narayan Mishra, Triptish Bhatia, et al.
Journal of Vascular Surgery. Venous and Lymphatic Disorders|June 12, 2022
Outcomes from a tertiary care center using a catheter thrombectomy system for managing acute iliofemoral deep vein thrombosisMichael A Jolly, Marie M Lockhart, Deep Shah, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|September 20, 2016
Correlation of Lipid Profile and Risk of Developing Type 2 Diabetes Mellitus in 10-14 Year Old ChildrenNusrath M Habiba, Kimberly G Fulda, Riyaz Basha, et al.
Clinical Breast Cancer|June 14, 2011
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell, Colin R James, Deep Shah, et al.
Clinical Breast Cancer|May 17, 2011
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri, Deep Shah, Jonathan Krell, et al.
Oncotarget|September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancerCarlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2015
PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab ResistanceKinnari Pandya, Debra Wyatt, Brian Gallagher, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1Deep Shah, Debra Wyatt, Andrew T Baker, et al.
The Indian Journal of Medical Research|March 6, 2020
Informed consent in psychiatry outpatientsSmita N Deshpande, Nagendra Narayan Mishra, Triptish Bhatia, et al.
Journal of Vascular Surgery. Venous and Lymphatic Disorders|June 12, 2022
Outcomes from a tertiary care center using a catheter thrombectomy system for managing acute iliofemoral deep vein thrombosisMichael A Jolly, Marie M Lockhart, Deep Shah, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|September 20, 2016
Correlation of Lipid Profile and Risk of Developing Type 2 Diabetes Mellitus in 10-14 Year Old ChildrenNusrath M Habiba, Kimberly G Fulda, Riyaz Basha, et al.
Clinical Breast Cancer|June 14, 2011
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell, Colin R James, Deep Shah, et al.
Clinical Breast Cancer|May 17, 2011
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri, Deep Shah, Jonathan Krell, et al.
Oncotarget|September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancerCarlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2015
PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab ResistanceKinnari Pandya, Debra Wyatt, Brian Gallagher, et al.
Pageof 4